

# **Clinical Trials Program**

Dr. Jonathan

ramson


Princess Margaret Cancer Centre

McMaster

University

# Clinical trial to test the oncolytic vaccine approach in combination with checkpoint inhibitor antibodies

June 10, 2015 to June 30, 2019



tumour immune response and provide their own ability to kill cancer cells. Onto this, the trial will layer an antibody therapy in the form of an immune checkpoint inhibitor. These inhibitors target immunological brakes, which normally function to hold the immune system at bay in order to avoid. its over-activation against normal cells. These immunological brakes are often co-opted by cancer cells, allowing the cancer to escape detection by the immune system. By using immune checkpoint inhibitors to disrupt this deception, the immune system can properly detect the cancer and do its job to get rid of the disease.

Because only some patients in clinical trials respond to therapeutic antibodies on their own, it's thought that immune checkpoint inhibitors are most effective in patients with an existing anticancer immune response. As a result, there is a search for agents that will sensitize cancers to immune checkpoint inhibitors. This trial will explore whether the proposed oncolytic virus vaccine approach will sensitize the cancer in this way, while also delivering its own cancer-killing properties.

# **Clinical trial** sites and investigators

Ottawa The Ottawa Hospital, University of Ottawa **Clinical investigators** Dr. Derek Jonker Dr. Michael Ong Dr. Guy Ungerechts Scientific investigator Dr. John Bell



Hamilton

Juravinski Cancer Centre,

Hamilton Health Sciences,

**Clinical investigator** 

Dr. Rosalyn Juergens

Dr. Jonathan Bramson

Dr. Brian Lichty

Scientific investigators

McMaster University

### Vancouver

BC Cancer Agency, University of British Columbia Scientific investigators Dr. Rob Holt Dr. Brad Nelson

## Toronto

Princess Margaret Cancer Centre University Health Network Clinical investigators Dr. Marcus Butler Dr. Natasha Leigh Dr. Amit Oza Dr. Albi Razak

**BioCanRx** \$750.000 approved on June 10, 2015

# **Partner contributions**

**Ontario Insitute for Cancer Research** \$745,321

**Turnstone Biologics** \$7,50,000

November 1, 2016

Trial opens

### Before November 1, 2016

- Generate required clinical and regulatory documents
- Submit Clinical Trial Application to Health Canada
- Establish contracts with sites and other contract research organizations, and obtain REB approvals
- Vial existing lot of the oncolytic vaccine MG1MA3
- Manufacture and release a second lot of the oncolytic vaccine MG1MA3

# September 1 to December 1, 2018

- · Complete follow-up and evaluation of:
  - primary safety objectives
  - secondary endpoint of response to treatment in the Phase 1b part of the study

# The power to kill cancer lies within us. Let's tell our bodies how.

### November 1, 2016 to April 1, 2017 Enrol and treat patients 1 to 6 in the initial safety phase of the trial

# April 1, 2017 to September 1, 2018

- Enrol and treat patients 7 to 12 in the initial safety phase of the trial
- Complete analysis of the first 12 patients and choose treatment schedule for the Phase 1b part of the trial
- Enrol and treat patients 13 to 42 in the Phase 1b part of the trial

## September 1, 2018 to June 1, 2019

 Continue and complete evaluation of the remaining secondary endpoints, which include: duration of response, antigen-specific T-cell activation, lymphocyte infiltration into tumours and biomarkers that predict tumour response Write manuscript

# Canada's Immunotherap Le réseau canadien d'immunothérapie